Last Updated on December 31, 2023 by The Health Master
Zydus Pharmaceuticals, Inc. has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin capsules at a strength of 34 mg.
Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, it added.
It further mentioned that the drug will be manufactured at the group’s formulation manufacturing facility at SEZ Ahmedabad.
USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection
USFDA gives nod to Granules India for Prazosin HCL capsules
USFDA gives nod to Lupin for this drug to treat Kidney disease
USFDA gives nod to Lupin generic Azilsartan Medoxomil tablets
USFDA authorises first oral antiviral to treat COVID
USFDA approves expanded use of Amgen’s psoriasis drug
Meting for 19 FDCs permitted pre-1988 postponed
DCGI gives approval to Biological E for Corbevax
USFDA gives tentative nod to Amphastar Pharma for Vasopressin injection
NPPA fixes retail price of 2 formulations: December 2021
NPPA fixes retail price of 28 formulations: December 2021
NPPA extends price cap on liquid Medical Oxygen and Oxygen inhalation
CDSCO approves Corbevax, Covovax and Molnupiravir for restricted use
Nutraceutical sector concerned over FSSAI’s notification on Marketers
We must learn to live with Covid: WHO
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
